Management of Severe COVID-19 Infection in Children: A Thera
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Although coronavirus disease 2019 (COVID-19) occurs in children, compared to adults they have milder disease. They are infrequently admitted to intensive care units, have a better prognosis and their mortality is low. However, because children are often asymptomatic or experience a mild disease the true incidence of COVID-19 in children may be higher. Infected children should be isolated and mild cases should receive supportive treatment at home. The use of antiviral or immunomodulatory therapies should only be considered within a clinical trial setting or on a case-to-case basis.

Pediatricians should be watchful for the uncommon but serious post-infectious Kawasaki-like, pediatric multisystem inflammatory syndrome related to COVID-19 which may occur several weeks following an asymptomatic or mild infection. Children with serious manifestations of COVID-19, such as septic shock, altered consciousness or multi-organ failure, severe acute respiratory distress syndrome, pediatric multisystem inflammatory syndrome, should be admitted to the hospital and receive supportive care, and organ support in case of organ failure. Administration of antiviral and immunomodulatory therapy may be required.

To achieve the maximal effect, antivirals should be administered as early as possible before clinical deterioration occurs. Therapeutic options include lopinavir/ritonavir and ribavirin for 7 days, and remdesivir for 10 days. Clinical trials of chloroquine and hydroxychloroquine in adults with COVID-19 infection have shown no efficacy.

Some children with acute respiratory distress syndrome manifest clinical features and serological markers seen in hyperinflammatory syndromes. The levels of these markers are often lower than those seen in other syndromes. These markers include chimeric antigen receptor T cell therapy-associated cytokine release syndrome, secondary hemophagocytic lymphohistiocytosis, and sepsis-associated macrophage activation-like syndrome. Most of the inflammation in COVID-19 occurs within the lungs. Children with the multisystem inflammatory syndrome should be treated with immunomodulatory therapy.

The decision to initiate antiviral and immunomodulatory therapy for COVID-19 should be made after careful consideration on an individual basis. This is because there is currently no proof of their effectiveness for COVID-19 in children and only limited clinical evidence in adults.

Therapeutic choices include humanized anti- interleukin 6 (IL-6) monoclonal antibody (tocilizumab), and a recombinant antagonist of the human IL-1 receptor (anakinra).

Corticosteroids may be helpful in the management of rapidly worsening chest imaging and the presence of acute respiratory distress syndrome, septic shock, toxic symptoms, encephalitis or encephalopathy, secondary hemophagocytic lymphohistiocytosis, and wheezing.

Those manifesting pediatric multisystem inflammatory syndrome with clinical features similar to Kawasaki disease should be treated with high-dose intravenous immunoglobulin, corticosteroids (methylprednisolone), aspirin, heparin, and immunomodulatory agents (e.g., tocilizumab and anakinra).

Respiratory support is essential in those with respiratory distress and includes non-invasive measures such as heated humidified oxygenation administered through nasal cannula or mask, continuous positive airway pressure, or high-frequency ventilation. Mechanical ventilation should be initiated if these measures fail.

Hemofiltration or hemodialysis may be necessary for those with multiple organ failure (especially acute kidney injury) or fluid overload. Plasma exchange is required to treat liver failure. Extracorporeal membrane oxygenation may be needed when mechanical ventilation or hemofiltration fails, and cardiopulmonary failure occurs.

More research is needed to better define and understand the disease course and pathophysiology of COVID-19 infection and pediatric multisystem inflammatory syndrome in children. Ongoing clinical trials investigating the use of antiviral and immunomodulatory agents may better define their role in the management of these conditions. Because of the paucity of solid evidence to support the therapeutic choices, the decision to initiate any of these treatments should be made carefully on an individual basis.

Source: https://theijcp.org/index.php/ijcp/article/view/404/341
Like
Comment
Share